Paragon Biosciences

What Paragon Biosciences does

Paragon Biosciences is a privately held life science company creator, builder, and investor founded by Jeff Aronin in 2017 and headquartered in Chicago. The firm operates a Create-Build-Fund model: it identifies large unmet medical needs, taps scientific expert networks to validate viability, builds dedicated biotech companies with internal expertise in clinical development, regulatory affairs, manufacturing, and commercialization, and funds them through Paragon's capital and external financial partners such as Bain Capital Life Sciences, Fidelity, OrbiMed, and NVIDIA's NVentures.

The portfolio spans five companies across CNS, rare disease, regenerative medicine, and AI-driven protein design. Harmony Biosciences (NASDAQ: HRMY) commercializes WAKIX (pitolisant) for narcolepsy and reported $437.9M in 2022 net product revenue (43% YoY growth), with WAKIX cumulative net revenue exceeding $2 billion by Q3 2025. Emalex Biosciences developed ecopipam, a first-in-class selective dopamine D1 receptor antagonist for Tourette syndrome that received FDA Orphan Drug and Fast Track designations, delivered positive Phase 3 data published in JAMA Neurology, and was sold to Teva Pharmaceutical in June 2026 for $700 million cash plus up to $200 million in commercial milestones and net-sales-based royalties. Evozyne operates a generative AI protein design platform (ProT-VAE built on NVIDIA BioNeMo) with programs in autoimmune disease, PKU, and cytokine engineering and a multi-target research collaboration with Takeda. Castle Creek Biosciences is in late-stage clinical development of a gene-modified cell therapy for dystrophic epidermolysis bullosa. CiRC Biosciences develops regenerative medicines including cell therapies for retinitis pigmentosa and Parkinson's disease.

Paragon's business model monetizes through equity stakes, milestone and royalty streams from strategic exits, and management and operational support across the portfolio. The operating company runs on a lean 11-50 person executive and functional team (clinical, legal, finance, technology, capital allocation) and does not sell products directly to end customers; revenue mechanics are episodic exits and retained equity appreciation rather than recurring ARR.

Name

Paragon Biosciences

Legal name

Paragon Biosciences, LLC

Website

https://paragonbiosci.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Paragon Biosciences is a private life science company creator and investor that builds and funds biotech companies addressing high unmet medical needs across neurology, rare diseases, regenerative medicine, and AI-driven protein therapeutics.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Company Creation and Investment

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAGAOAA

Clinical Operations & Monitoring FSP (CRA/CTM/Start-up)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)

SECONDARYHLAGAOAO

Commercial, Sales & Field Medical (MSL) Staffing FSP

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)

SECONDARYHLAGAOAG

Medical Affairs, Scientific Communications & HEOR FSP

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)

Keywords

• Biotech company creation
• Life sciences investment
• Biopharmaceutical incubation
• Drug development platform
• Portfolio biotech builder

Headquarters

HQ city

Chicago

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Portfolio company exits: Paragon generates returns through building biotech companies and selling them via strategic transactions. The sale of Emalex Biosciences to Teva for $700M cash plus up to $200M in milestones demonstrates this model.
2. Portfolio company value creation: Paragon retains ownership stakes in portfolio companies like Harmony Biosciences (NASDAQ: HRMY) which generates commercial revenue from product sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Paragon Biosciences is a global life science company that creates, builds and funds innovative biology-based companies. It identifies large unmet medical needs, taps expert networks to assess scientific viability, builds durable businesses by providing clinical, regulatory, financial and operational expertise, and funds portfolio companies alongside external capital partners. Portfolio companies advance therapies through clinical development to commercial milestones or strategic exits.

Product overview

Paragon Biosciences is a global life science leader that creates, builds and funds innovative biology-based companies. The company operates as a company creator/investor with a portfolio of portfolio companies across multiple therapeutic areas: Emalex Biosciences (CNS, acquired by Teva for $700M) developed ecopipam for Tourette syndrome; Harmony Biosciences (NASDAQ:HRMY) commercializes WAKIX for narcolepsy; Evozyne uses generative AI to design novel protein therapeutics; Castle Creek Biosciences develops gene therapy for epidermolysis bullosa; and CiRC Biosciences creates regenerative medicines including cell therapies for retinitis pigmentosa and Parkinson's disease. Paragon provides expertise in clinical development, regulatory affairs, manufacturing, and commercialization to advance portfolio companies through the create-build-fund model.

Differentiator

Problem solved

Functional benefit

Products and services

• Emalex Biosciences (Portfolio Company) Paragon-founded portfolio company that developed ecopipam, a first-in-class selective dopamine D1 receptor antagonist for pediatric Tourette syndrome that completed Phase 3 trials and was registration-ready; acquired by Teva Pharmaceutical.
• Harmony Biosciences (Portfolio Company) Nationally listed (NASDAQ: HRMY) Paragon-founded portfolio company that develops and commercializes innovative therapies for patients with rare neurological diseases, led by WAKIX (pitolisant) for narcolepsy.
• Evozyne (Portfolio Company) Paragon-founded portfolio company that applies generative AI (ProT-VAE model on NVIDIA BioNeMo) to design novel therapeutic proteins, including programs for autoimmune disease, PKU, and engineered cytokines.
• Castle Creek Biosciences (Portfolio Company) Paragon-founded portfolio company developing a gene-modified cell therapy for dystrophic epidermolysis bullosa (DEB) in Phase 3 pivotal study and expanding into additional severe skin and connective tissue disorders.
• CiRC Biosciences (Portfolio Company) Paragon-founded portfolio company developing regenerative cell therapies through cellular reprogramming, including cell therapy for retinitis pigmentosa, neuron replacement for Parkinson's disease, and other CNS indications.
• WAKIX (pitolisant) FDA-approved first-in-class selective histamine H3 receptor antagonist/inverse agonist for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy, commercialized by portfolio company Harmony Biosciences.

Quantifiable outcome

• Emalex sold to Teva for $700M + $200M milestones after advancing ecopipam through Phase 3
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Partnerships

Three partnerships are on record, tiered major.

• Teva PharmaceuticalmajorStrategic or Co-development Partner · 11 June 2026Teva acquired Emalex Biosciences from Paragon for $700M cash plus up to $200M in milestone payments and royalties. Emalex developed ecopipam, a first-in-class treatment for Tourette syndrome that completed Phase 3 trials and is registration-ready.
• NVIDIAmajorTechnology or Integration · 12 January 2023Evozyne collaborated with NVIDIA to create an AI model (ProT-VAE) for novel protein design using NVIDIA BioNeMo framework. The partnership exponentially increases synthetic protein design capabilities.
• TakedamajorStrategic or Co-development Partner · 5 April 2022Evozyne entered a multi-target research collaboration and license agreement with Takeda to develop next-generation gene therapies, building on their initial strategic collaboration.

Scale indicators3 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Flagship Pioneering: Flagship Pioneers and grows breakthrough companies in life sciences and sustainability, originating and building biotech platforms—directly comparable to Paragon's company-creation engine.
• Roivant Sciences: Roivant creates, funds, and operates subsidiary biotech 'Vants' across multiple therapeutic areas with a focus on developing and commercializing innovative therapies—directly comparable to Paragon's create-build-fund model.
• PureTech Health: PureTech is a clinical-stage biotherapeutics company that creates and develops novel medicines through a hub-and-spoke model—directly comparable to Paragon's portfolio of biology-based companies.
• BridgeBio Pharma: BridgeBio develops genetic disease therapies through multiple subsidiaries focused on rare diseases—comparable in scope and therapeutic-area focus (rare/neurological) to Paragon's portfolio.
• Centessa Pharmaceuticals: Centessa operates a portfolio of independently run biotech programs under one holding company, advancing multiple clinical-stage assets—comparable to Paragon's multi-portfolio structure.

Broad incumbents

• ARCH Venture Partners: ARCH is a long-established biotech venture firm that co-creates and funds early-stage life sciences companies—comparable to Paragon as a capital and operating partner for biotech origination.
• Atlas Venture: Atlas Venture builds early-stage biotech companies from inception through clinical proof-of-concept—comparable to Paragon as an active biotech company creator.

Others

• OrbiMed: OrbiMed is a leading healthcare investment firm that co-led Evozyne's $81M Series B—a relevant financial peer and ecosystem participant to Paragon.
• Bain Capital Life Sciences: Bain Capital Life Sciences is a major healthcare-dedicated investment firm and direct capital partner (led Emalex's $250M Series D)—a relevant financial peer and ecosystem participant to Paragon.

Emerging players

• Recursion Pharmaceuticals: Recursion uses AI/ML-driven drug discovery to build a portfolio of therapeutic programs—comparable to Evozyne's AI-native protein design capability within Paragon.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/paragon-biosciences-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries5 records

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Paragon Biosciences